PUNE, India, November 22, 2017 /PRNewswire/ --
Genome Editing/Genome Engineering Market is forecast to reach $6.28 billion by 2022 from $3.19 billion in 2017 at a CAGR of 14.5% during (2017-2022) driven by rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics.
Browse 96 Market Data Tables and 42 Figures spread through 164 Pages and in-depth TOC on "Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs) - Global Forecast 2022" http://www.rnrmarketresearch.com/genome-editing-genome-engineering-market-by-application-cell-line-engineering-animal-plant-genetic-engineering-technology-crispr-antisense-talen-zinc-finger-nuclease-end-user-biotechno-market-report.html .
The major players in the global genome editing/genome engineering market are Thermo Fisher Scientific (US), Merck (Germany), Horizon Discovery Group (UK), GenScript (US), Sangamo BioSciences (US), Integrated DNA Technologies (US), Lonza Group (Switzerland), New England Biolabs (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland).
North America to dominate the genome editing/genome engineering market and is projected to grow at the highest CAGR during the forecast period. The North American region is expected to hold the largest share of the global market in 2017. This regional segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate of this region can be attributed to factors such as the development of gene therapy in the US, increasing use of genetically modified crops, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding.
Inquire for Discount on "Genome Editing/Genome Engineering Market - Global Forecast 2022" research report at http://www.rnrmarketresearch.com/contacts/discount?rname=378176 .
By technology, the genome editing/genome engineering market is segmented into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is estimated to grow at the highest CAGR during the forecast period. The ease of use associated with the CRISPR technology is a significant advantage over ZFN and TALEN, especially in generating a large set of vectors to target numerous sites or even genome-wide libraries. Another potential advantage of CRISPR is its ability to multiplex, that is, to use multiple guide RNAs in parallel to target multiple sites simultaneously in the same cell. This makes it easier to mutate multiple genes at once or engineer precise deletions in a genomic region.
On the basis of end user, the genome editing/genome engineering market is classified into pharmaceutical and biotechnology companies, academic & government research institutes, and contract research organizations. The pharmaceutical and biotechnology companies segment is estimated to grow at the fastest rate during the forecast period. The increasing prevalence of infectious diseases and cancer are driving research activities worldwide; this is expected to drive the demand for genome editing in biotechnology & pharmaceutical companies.
Order a copy of "Genome Editing/Genome Engineering Market - Global Forecast 2022" research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=378176 .
The report analyzes the genome editing/genome engineering market and aims at estimating the market size and the future growth potential of this market based on various segments such as technology, application, end user, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
The cell line engineering to dominate the genome editing/genome engineering market during the forecast period. Break of primary participants was as mentioned below:
Explore more reports on Biotechnology Market at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology .
Advertisement
Genome Editing/Genome Engineering Market is forecast to reach $6.28 billion by 2022 from $3.19 billion in 2017 at a CAGR of 14.5% during (2017-2022) driven by rising government funding and growth in the number of genomics projects, high prevalence of infectious diseases and cancer, technological advancements, increasing production of genetically modified crops, and growing application areas of genomics.
Advertisement
Browse 96 Market Data Tables and 42 Figures spread through 164 Pages and in-depth TOC on "Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical Companies, CROs) - Global Forecast 2022" http://www.rnrmarketresearch.com/genome-editing-genome-engineering-market-by-application-cell-line-engineering-animal-plant-genetic-engineering-technology-crispr-antisense-talen-zinc-finger-nuclease-end-user-biotechno-market-report.html .
The major players in the global genome editing/genome engineering market are Thermo Fisher Scientific (US), Merck (Germany), Horizon Discovery Group (UK), GenScript (US), Sangamo BioSciences (US), Integrated DNA Technologies (US), Lonza Group (Switzerland), New England Biolabs (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland).
North America to dominate the genome editing/genome engineering market and is projected to grow at the highest CAGR during the forecast period. The North American region is expected to hold the largest share of the global market in 2017. This regional segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate of this region can be attributed to factors such as the development of gene therapy in the US, increasing use of genetically modified crops, rising prevalence of infectious diseases and cancer, and rising availability of research grants and funding.
Inquire for Discount on "Genome Editing/Genome Engineering Market - Global Forecast 2022" research report at http://www.rnrmarketresearch.com/contacts/discount?rname=378176 .
By technology, the genome editing/genome engineering market is segmented into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is estimated to grow at the highest CAGR during the forecast period. The ease of use associated with the CRISPR technology is a significant advantage over ZFN and TALEN, especially in generating a large set of vectors to target numerous sites or even genome-wide libraries. Another potential advantage of CRISPR is its ability to multiplex, that is, to use multiple guide RNAs in parallel to target multiple sites simultaneously in the same cell. This makes it easier to mutate multiple genes at once or engineer precise deletions in a genomic region.
On the basis of end user, the genome editing/genome engineering market is classified into pharmaceutical and biotechnology companies, academic & government research institutes, and contract research organizations. The pharmaceutical and biotechnology companies segment is estimated to grow at the fastest rate during the forecast period. The increasing prevalence of infectious diseases and cancer are driving research activities worldwide; this is expected to drive the demand for genome editing in biotechnology & pharmaceutical companies.
Order a copy of "Genome Editing/Genome Engineering Market - Global Forecast 2022" research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=378176 .
The report analyzes the genome editing/genome engineering market and aims at estimating the market size and the future growth potential of this market based on various segments such as technology, application, end user, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
The cell line engineering to dominate the genome editing/genome engineering market during the forecast period. Break of primary participants was as mentioned below:
- By Company Type: Tier 1 - 56%, Tier 2 - 35%, and Tier 3 - 9%
- By Designation: C-level - 27%, Director Level - 15%, Others - 58%
- By Region: North America - 37%, Europe - 23%, Asia-Pacific - 25%, RoW - 15%
Explore more reports on Biotechnology Market at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Hrishikesh Patwardhan
2nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune - 411001.
Maharashtra, India.
+1-888-391-5441
[email protected]
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed
SOURCE RnRMarketResearch
